Seedchrony provides a non-invasive diagnostic platform that assesses uterine readiness for embryo transfer in real time, aiming to increase pregnancy rates by 30%. By reading endometrial biomarker data without biopsy, the technology gives clinicians immediate, accurate insights to guide more effective and individualized embryo transfers. The platform is designed to address the fact that embryo transfer success rates currently remain below 40%.
Funding
Funding not disclosed
Founders
Product
Problem
Embryo transfer success rates remain below 40%, and a key factor limiting success is the status of the maternal endometrium during implantation. Current methods for assessing endometrial receptivity often require invasive biopsies, which can compromise the endometrial lining and delay treatment, leaving clinicians without timely or accurate information to guide transfer decisions.
Solution
Seedchrony provides a non-invasive diagnostic platform that assesses uterine readiness for embryo transfer in real time. By reading biomarker data directly from the uterus without the need for a biopsy, the technology preserves endometrial integrity while delivering immediate and accurate results. This allows clinicians to make better-informed decisions about endometrial receptivity, enabling more effective and individualized embryo transfers. The platform is designed to increase pregnancy rates by 30% by supporting clinicians with real-time data on the optimal timing and condition for transfer.
Target Audience
Primary customers are IVF specialists, reproductive endocrinologists, and assisted reproduction clinics seeking to improve embryo transfer outcomes and personalize treatment for patients with implantation challenges.
Features
- Non-invasive biomarker analysis that eliminates the need for endometrial biopsy
- Real-time results that provide immediate clinical decision support during embryo transfer workflows
- High accuracy in assessing uterine receptivity, enabling personalized transfer timing
- Preserves endometrial integrity, reducing risk and improving patient comfort
- Designed to increase pregnancy rates by up to 30% through improved receptivity assessment